The multinational Hepatitis B and HIV Cure Consortium, colloquially known as the BICC, was recently established through the awarding of a five-year, $24 million grant from NIH’s National Institute of Allergy and Infectious Diseases.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe






